WebOpticyte, Inc. 5731 58TH AVE NE Seattle, WA 98105-2024 United States DUNS: 079420841 HUBZone Owned: No Woman Owned: No Socially and Economically Disadvantaged: No Principal Investigator Name: LORILEE ARAKAKI Phone: (206) 250-4827 Email: [email protected] Business Contact Name: KENNETH SCHENKMAN Phone: … WebSerum Tears Made Simple. At Vital Tears, our mission is to make serum tears easily available and affordable for every patient. We've done that for over 10,000 people since …

Opticyte Earns FDA Breakthrough Device Designation for the First …

WebDavison is partnering with Opticyte to bring holistic dry eye therapies to her Smyrna location. Call or text to schedule an appointment for a dry eye evaluation. Now offering Autologous Serum... WebOpticyte, Inc. * 2 Principals See who the company's key decision makers are 4 Contacts Reach the right people with access to detailed contact information. 5 See similar … billy talent fallen leaves bass tab

Opticyte Earns FDA Breakthrough Device Designation for the First …

WebFind company research, competitor information, contact details & financial data for Opticyte, Inc. of Seattle, WA. Get the latest business insights from Dun & Bradstreet. WebOpticyte has raised a total of $5.7M in funding over 3 rounds. Their latest funding was raised on Nov 1, 2024 from a Seed round. Opticyte is funded by 4 investors. SWAN Venture Fund … WebRecognized by the FDA as a Breakthrough Device, the Opticyte Cell O₂ Monitor is the first device to measure oxygen levels inside cells in real time. Organ failure results from … The Opticyte Cell O₂ Monitor shines light in the visible and near-infrared spectrum … Opticyte’s Cell O₂ Monitor holds the promise to reduce organ failure and death … Opticyte has been capital-efficient and is funded for the next year with a non … Opticyte Earns FDA Breakthrough Device Designation for the First Cell O 2 Patient … Opticyte is a medical device company dedicated to developing the first and only … cynthia facilities trinity college